-
Product Insights
New![]()
Net Present Value Model: Innate Pharma SA’s Monalizumab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Innate Pharma SA’s Lacutamab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Innate Pharma SA – Company Profile
Innate Pharma SA (Innate Pharma) is a biotechnology company that develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL), Monalizumab, an immune checkpoint inhibitor targeting solid tumors, head and neck cancer, and Avdoralimab antibody against bullous pemphigoid. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101 and IPH62...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YSHBV-001 in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.YSHBV-001 in Hepatitis BDrug Details:YSHBV-001 is under development for the prevention of hepatitis B virus infections....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Neuroinflammation in Neuroinflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Neuroinflammation in NeuroinflammationDrug Details:Recombinant plasma gelsolin (pGSN) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement for Infectious Disease in Acute Lung Injury
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Plasma Gelsolin Replacement for Infectious Disease in Acute Lung Injury Drug Details: Recombinant plasma...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in Trauma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in TraumaDrug Details:Recombinant plasma gelsolin is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Cystic Fibrosis And Bronchiectasis in Bronchiectasis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Cystic Fibrosis And Bronchiectasis in Bronchiectasis Drug Details:Recombinant plasma gelsolin (pGSN)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in Burns
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Recombinant Plasma Gelsolin Replacement For Arthritis, Inflammation, Trauma And Burns in Burns Drug Details:Recombinant plasma gelsolin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement for Infectious Disease in Sepsis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Plasma Gelsolin Replacement for Infectious Disease in Sepsis Drug Details: Recombinant plasma gelsolin (pGSN)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cibinetide in Diabetic Macular Edema
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Cibinetide in Diabetic Macular Edema Drug Details: Cibinetide is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Low-Grade Glioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Low-Grade GliomaDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease 2019...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Malignant Pleural Mesothelioma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Malignant Pleural MesotheliomaDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Metastatic Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Metastatic Colorectal CancerDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Metastatic Adenocarcinoma of The Pancreas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Metastatic Adenocarcinoma of The PancreasDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Breast CancerDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease 2019...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Prostate CancerDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease 2019...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Metastatic Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Metastatic Breast CancerDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Non-Small Cell Lung CancerDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Poly-ICLC in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Poly-ICLC in Pancreatic Ductal AdenocarcinomaDrug Details:Poly-ICLC (Hiltonol) is under development for the treatment of Coronavirus disease...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.